Shares of BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI) fell 5.7% during mid-day trading on Monday . The stock traded as low as $2.51 and last traded at $2.82, with a volume of 2,405,799 shares changing hands. The stock had previously closed at $2.99.

Separately, Maxim Group reissued a “buy” rating and issued a $5.00 price objective on shares of BrainStorm Cell Therapeutics in a research report on Saturday, June 4th.

The stock’s market cap is $50.55 million. The firm has a 50 day moving average price of $2.48 and a 200-day moving average price of $2.42.

BrainStorm Cell Therapeutics (NASDAQ:BCLI) last posted its quarterly earnings data on Tuesday, May 10th. The biotechnology company reported ($0.10) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.25) by $0.15. On average, equities research analysts predict that BrainStorm Cell Therapeutics Inc. will post ($0.58) earnings per share for the current fiscal year.

Brainstorm Cell Therapeutics Inc is a biotechnology company. The Company is engaged in developing adult stem cell therapies for debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig’s disease), Multiple Sclerosis (MS) and Parkinson’s disease (PD), among others.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.